Company news
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news
Every Arrowhead Pharmaceuticals, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 5
Arrowhead Pharmaceuticals Initiates Phase 2b Study of ARO-APOC3 for Treatment of Mixed Dyslipidemia
September 30, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming October 2021 Conferences
September 29, 2021
Arrowhead Earns $10 Million Phase 1 Milestone Payment
September 28, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming September 2021 Conferences
September 1, 2021
Arrowhead Pharmaceuticals Reports Fiscal 2021 Third Quarter Results
August 5, 2021
Arrowhead Pharmaceuticals Receives Breakthrough Therapy Designation from U.S. FDA for ARO-AAT for the Treatment of Alpha-1 Antitrypsin Deficiency Associated Liver Disease
July 29, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Third Quarter Results
July 14, 2021
Arrowhead Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 14, 2021
Arrowhead Announces Positive Interim Results from Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
July 6, 2021
Arrowhead Pauses ARO-ENaC Phase 1/2 Clinical Study
July 2, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia
June 30, 2021
Arrowhead Presents Additional Clinical Data on Investigational ARO-AAT Treatment in Patients with Alpha-1 Liver Disease at EASL International Liver Congress
June 26, 2021
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress
June 25, 2021
Arrowhead Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH at EASL International Liver Congress
June 23, 2021
Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout
June 21, 2021
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia
June 3, 2021
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
June 2, 2021
Arrowhead Earns $10 Million Option Exercise Fee
May 18, 2021
Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
May 4, 2021
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
April 28, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results
April 16, 2021
Arrowhead Announces ARO-DUX4 as First Muscle Targeted RNAi Candidate Using TRiMTM Platform
April 15, 2021
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
March 1, 2021
Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results
February 4, 2021
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
January 25, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
January 19, 2021
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
December 7, 2020
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer
December 2, 2020
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
November 25, 2020
Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
November 23, 2020
Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
November 13, 2020
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
November 13, 2020
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
November 4, 2020
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results
November 2, 2020
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
October 8, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
September 30, 2020
Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
September 16, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
September 8, 2020
Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors
September 8, 2020
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
August 31, 2020
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
August 28, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences
August 18, 2020
Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
August 18, 2020
Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
August 11, 2020
Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
August 5, 2020
Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
July 29, 2020
Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
July 28, 2020
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
July 9, 2020
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results
July 8, 2020
Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences
May 28, 2020